Voyager Therapeutics (VYGR) Tops Q2 EPS by 6c

Voyager Therapeutics (NASDAQ: VYGR) reported Q2 EPS of ($0.51), $0.06 better than the analyst estimate of ($0.57). Revenue for the quarter came in at $4.85 million versus the consensus estimate of $1.6 million.

For earnings history and earnings-related data on Voyager Therapeutics (VYGR) click here.

You May Also Be Interested In

• SanDisk and Micron surge as Apple confirms memory price pass-through
• Wall Street scrambles to lift Micron price targets ahead of earnings
• Vail Resorts taps bankers for potential activist defense, Semafor reports